Announcement on Use of Own Funds, Bank Acceptance Bills and Other Methods to Pay Funds Required for Raised Fund Investment Projects and Equivalent Replacement with Raised Funds
Securities code: 688488 Securities abbreviation: Aidi Pharmaceutical Announcement number: 2026-059 Jiangsu Aidi Pharmaceutical Group Co., Ltd.
Announcement on using self-owned funds, bank acceptance bills, etc. to pay for the funds required for raised investment projects and replacing them with raised funds in equal amounts
The company's board of directors and all directors guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its contents in accordance with the law.
Jiangsu Aidi Pharmaceutical Group Co., Ltd. (hereinafter referred to as "Aidi Pharmaceutical" or the "Company") held the 17th meeting of the third board of directors on July 30, 2026, and reviewed and approved the "Proposal on Using Own Funds, Bank Acceptance Bills and Other Methods to Pay the Funds Required for Raised Investment Projects and Replace them with Raised Funds in Equal Parts", and agreed to use its own funds without affecting the normal implementation of the raised investment projects. , bank acceptance bills and other methods to pay the funds required for the raised investment project, and regularly transfer equal amounts of funds from the raised funds special account to the company's own capital account for equal replacement. This part of the equal amount of replacement funds is regarded as the funds used for the raised investment project. The above matters do not need to be submitted to the company's shareholders' meeting for review. The sponsoring agency Guolian Minsheng Securities Underwriting and Sponsoring Co., Ltd. (hereinafter referred to as the "sponsor") has issued verification opinions on the above matters. The relevant information is now announced as follows:
1. Basic situation of raised funds
As approved by the China Securities Regulatory Commission, the company issued 60 million RMB ordinary shares to the public at an issue price of RMB 13.99 per share and raised total funds of RMB 839,400,000.00. Yuan, after deducting underwriting fees and sponsorship fees, the total tax-included amount was 61,758,000.00 yuan, and the actual funds raised were 777,642,000.00 yuan. The cumulative issuance expenses of this stock issuance include tax of RMB 79,833,781.03, including the deductible value-added tax input tax of RMB 4,506,826.42. After deducting the tax-exclusive issuance expenses, the net amount of funds raised is RMB 764,073,045.39.
The above-mentioned raised funds were all received on July 13, 2020. Rongcheng Accounting Firm (Special General Partnership) verified the arrival of the funds raised in this issuance and issued Rongcheng Yanzi [2020] No. 210Z0012 "Capital Verification Report". The company carries out special account storage management for the above-mentioned raised funds in accordance with regulations, and has signed a special account storage supervision agreement for raised funds with the sponsor institution and the raised funds special account supervision bank.
2. Basic situation of investment projects with raised funds
Up to now, the basic situation of the company’s investment projects is as follows:
Commitment to raise funds
Serial number Project name Project content Total project progress capital (10,000 yuan)
iBand® (Enoveline Tablets)
10,050.00 Completed phase III clinical and post-marketing studies
Innovative drug research and development
1 Development Technology Center Building ACC008Ⅲ/Ⅳ clinical phase 9,020.00 Completed purchase project Integrase inhibitor drug research and development and
15,446.99 Clinical research projects in progress
HIV high-end generic drug R&D project 3,700.00 In progress 2 API production R&D and supporting facilities project 20,330.00 Completed 3 Repay bank loan and supplement working capital 15,000.00 Total amount completed 73,546.99 -
For details on the use of raised funds as of December 31, 2025, please refer to the "Special Report of Jiangsu Aidi Pharmaceutical Group Co., Ltd. on the Storage and Actual Use of Raised Funds in 2025" disclosed by the company on the Shanghai Stock Exchange website (www.sse.com.cn) on March 31, 2026 (Announcement Number: 2026-039).
- Reasons for using self-owned funds, bank acceptance bills, etc. to pay for the funds required for a raised investment project and replacing them with raised funds in equal amounts
During the implementation of the raised investment project, according to the principle of earmarking the raised funds, all expenditures should in principle be directly paid and transferred from the special account of raised funds. However, during the implementation of the raised investment project, the company sometimes uses its own funds, bank acceptance bills, etc. to pay part of the funds for the raised investment project. The main reasons are as follows:
(1) During the implementation of the company's fundraising projects, it is necessary to pay personnel wages (including personal income tax, social insurance, provident fund, etc.), bonuses and other expenses. According to the "Measures for the Administration of RMB Bank Settlement Accounts" of the People's Bank of China, the payment of employee salaries should be handled through the company's basic deposit account and cannot be paid directly through the special account for raised funds;
(2) When the raised investment project involves the purchase of equipment, materials, services, etc. from overseas, it is subject to the functional restrictions of the raised funds account, and needs to pay the overseas supplier in foreign exchange, and direct cash payment cannot be made through the raised funds account; at the same time, customs import value-added tax and other taxes must be paid uniformly from the bank account bound by the company and the customs, and cannot be paid directly through the raised funds account;
(3) The company pays the funds involved in the investment project in the form of bank acceptance bills according to actual needs (such as equipment purchase payments, material purchase payments, and other related required funds, etc.), which will help speed up the company's bill turnover, improve the efficiency of fund use, and reduce financial costs.
Therefore, in order to improve the efficiency of the use of raised funds and the efficiency of the implementation of raised investment projects, the company and its subsidiaries, as the implementation entities, pay the relevant raised fund investment project expenses in advance with their own funds, bank acceptance bills, etc. during the implementation of the raised investment projects, and regularly withdraw corresponding amounts from the special account of raised funds to replace the amounts paid by the company with its own funds.
- The operational process of using self-owned funds, bank acceptance bills, etc. to pay for the funds required for a raised investment project and replacing them with raised funds in equal amounts.
In order to further strengthen the management of the use of raised funds, the company plans to use its own funds, bank acceptance bills and other methods to pay for the funds required for the raised investment projects according to the actual situation during the implementation period of the raised investment projects, and replace them with the raised funds in equal amounts. The specific operation process is as follows:
(1) Based on the implementation progress of the investment projects and the expenditure content of the investment projects, the company's financial department regularly prepares detailed schedules for payment of funds for the investment projects using its own funds, bank acceptance bills, etc., and shall be reviewed and approved by the financial person in charge;
(2) After the payment process is approved, the company's financial department will transfer equal amounts of funds from the raised capital account to replace the raised investment project funds that have been paid with its own funds, bank acceptance bills, etc.;
(3) The company's financial department needs to establish a ledger for the replacement of raised funds, record the transaction contents of the special account of raised funds transferred to the basic deposit account or general deposit account, and notify the sponsor representative regularly.
In addition, the sponsor institution and the sponsor representative shall continue to supervise the company's use of its own funds, bank acceptance bills, etc. to pay for the funds required for the investment project and replace it with the raised funds in equal amounts, and have the right to regularly or irregularly inspect the company's use of the raised funds. The company and the depository bank of the raised funds shall cooperate with the sponsor institution's supervision and inspection work.
5. Impact on the company’s daily operations
The company and its subsidiaries that implement the raised investment projects will use their own funds, bank acceptance bills and other methods to pay for the funds required for the raised investment projects and replace them with raised funds in equal amounts based on the specific conditions of the raised investment projects. This will help improve the efficiency of fund use and will not affect the company's normal development of the investment projects and daily operations of the raised funds. There will be no disguised changes in the use of raised funds or damage to the interests of the company and shareholders.
6. Relevant review procedures
The company held the 17th meeting of the third board of directors on July 30, 2026, and reviewed and approved the "Proposal on using self-owned funds, bank acceptance bills, etc. to pay for the funds required for investment projects and replacing them with raised funds in equal amounts." This proposal does not need to be submitted to the company's shareholders' meeting for review.
7. Explanation of special opinions
(1) Opinions of the Audit Committee
The company and its subsidiaries that implement fundraising projects use their own funds, bank acceptance bills, etc. to pay the funds required for the fundraising projects in advance, and then regularly replace them with raised funds in equal amounts. They have performed necessary decision-making procedures and formulated corresponding operating procedures, which can effectively ensure the normal development of fundraising projects, improve the efficiency of the use of raised funds, and comply with the relevant regulations of the China Securities Regulatory Commission and the Shanghai Stock Exchange on the use of raised funds by listed companies. There is no disguised change in the use of raised funds or damage to the interests of the company and shareholders. Therefore, the Audit Committee agreed with the content of the "Proposal on using self-owned funds, bank acceptance bills, etc. to pay for the funds required for the raised investment project and replacing it with the raised funds in equal amounts."
(2) Opinions of the board of directors
The company uses its own funds, bank acceptance bills and other methods to pay for the funds required for the investment projects and replace them with raised funds in equal amounts, which is conducive to improving the efficiency of the use of funds, reducing the cost of using funds, and is in the interests of shareholders and investors. It does not affect the normal operation of the company's investment projects with raised funds, and does not change the investment direction of raised funds in disguise and harm the interests of shareholders. It is in compliance with relevant laws and regulations, normative documents such as the "Supervisory Rules for Raised Funds of Listed Companies" and the company's "Raised Funds Management System" and other relevant regulations.
(3) Opinions of the sponsor
After verification, the sponsor institution believes that: Aidi Pharmaceutical and its subsidiaries that implement the investment projects use their own funds, bank acceptance bills, etc. to pay for the funds required for the investment projects and replace them with raised funds in equal amounts. The matter has been reviewed and approved by the company's board of directors and the audit committee. This is an arrangement made by the company based on the objective needs of the implementation of the investment projects with raised funds and will not affect the company's investment projects. It is carried out normally and there is no disguised change in the use of raised funds, which is in compliance with the relevant laws, regulations and normative documents such as the "Supervisory Rules for Listed Companies' Raised Funds", "Shanghai Stock Exchange's Science and Technology Innovation Board Stock Listing Rules", "Shanghai Stock Exchange's Self-Regulatory Supervision Guidelines for Companies Listed on Science and Technology Innovation Board No. 1 - Standardized Operation" and the company's raised funds management system.
In summary, the sponsor institution has no objection to the company using its own funds, bank acceptance bills and other methods to pay for the funds required for the investment project and replacing them with the raised funds in equal amounts.
8. Online announcement attachment
"Verification Opinions of Guolian Minsheng Securities Underwriting and Sponsoring Co., Ltd. on Jiangsu Aidi Pharmaceutical Group Co., Ltd.'s use of its own funds, bank acceptance bills, etc. to pay for the funds required for raised investment projects and replace them with raised funds in equal amounts"
Announcement is hereby made.
Board of Directors of Jiangsu Aidi Pharmaceutical Group Co., Ltd.
July 31, 2026